eligibility_summary
Adults ≥18 with metastatic/extensive-stage SCLC. 1A/1B: progressed after platinum, 1B backfill & Part 3: 1L maintenance after ≥4 cycles platinum/etoposide+anti‑PD‑L1 with CR/PR/SD, 1C/4: no prior systemic tx. ECOG 0–1, measurable disease, tissue sample, life expectancy ≥3 mo. Exclude: other active malignancy, brain mets/LM unless stable/asx (P2–4), recent tx/RT/sx, organ/cardiac dz, immunodef/IS or live vax, pneumonitis/autoimmune lung dz, pregnancy, strong CYP3A/2D6 inhib, prior IO per part.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests: ZL-1310 (investigational immunotherapy), atezolizumab (anti–PD-L1 monoclonal antibody checkpoint inhibitor), and carboplatin (platinum cytotoxic chemotherapy). Mechanisms: The record doesn’t disclose ZL-1310’s MoA, protocol exclusions for prior CD137 agonists and other immunostimulants suggest ZL-1310 is a 4‑1BB (CD137) costimulatory agonist, likely an antibody, intended to activate/expand cytotoxic T cells and NK cells. Atezolizumab blocks PD‑L1 interaction with PD‑1/B7.1 to restore T‑cell antitumor activity. Carboplatin forms DNA crosslinks, causing tumor cell death and potentially increasing tumor immunogenicity. Target cells/pathways: CD137 on activated T/NK cells (costimulation), PD‑L1/PD‑1 checkpoint on tumor and immune cells (T‑cell reinvigoration), and tumor DNA damage pathways in SCLC cells (platinum adducts, apoptosis).